Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 2/20 | 0.64 |
| ▸ | CPB1 | P15086 | 1/20 | 0.64 |
| ▸ | CPA3 | P15088 | 1/20 | 0.64 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29154468 | 0.88 | MEN1 (0.59) | MEN1KMT2APOLB | |
| SCHEMBL12335729 | 0.85 | MEN1 (0.71) | MEN1KMT2A | |
| SCHEMBL7271417 | 0.83 | MME (0.65) | CPA3MEN1KMT2A | |
| SCHEMBL2685653 | 0.79 | CPA1 (0.72) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL14853314 | 0.79 | HDAC1 (0.61) | MEN1KMT2APOLB | |
| SCHEMBL11248580 | 0.79 | CPA3 (0.72) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL12517132 | 0.79 | LTA4H (0.64) | CPA1CPB1CPA3CPB2MEN1 | |
| SCHEMBL393002 | 0.78 | CPA1 (1.00) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL1915564 | 0.78 | CPA1 (1.00) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL5688996 | 0.78 | CPA1 (1.00) | CPA1CPB1CPA3CPB2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1486488-B1 | Use of a compound of formula I for making a pharmaceutical composition | BIONDI RICARDO MIGUEL (DE) | 2009-10-28 | — | — | EP | disclosed |
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | BIONDI RICARDO M | 2007-02-08 | — | — | US | disclosed |
| WO-2004111008-A2 | USE OF A COMPOUND OF FORMULA I FOR MAKING A PHARMACEUTICAL COMPOSITION | BIONDI RICARDO MIGUEL (DE) | 2004-12-23 | — | — | WO | disclosed |
| EP-1486488-A1 | Use of a compound of formula I for making a pharmaceutical composition | Phosphosites GmbH (DE) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | CYP7A1, UGT1A1, CYP2F1 | CPA1 156/4885CPB1 553/4885CPA3 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.